AMAG Pharmaceuticals Inc.

BioTrends Releases Three Publications - TreatmentTrends: US Nephrology, TreatmentTrends: Renal Dietitians, and TreatmentTrends: Anemia Managers - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism.
Diabetes Week; 11/16/2009; 1478 words; ...BioTrends Research Group, Inc.). Similar reports...study were released and AMAG Pharmaceuticals launched their new IV...ESAs. Familiarity with AMAG's Feraheme, on the...BioTrends Research Group, Inc. BioTrends Research...custom market research to pharmaceutical manufacturers ...

BioTrends Releases Three Publications - TreatmentTrends[R]: US Nephrology, TreatmentTrends[R]: Renal Dietitians, and TreatmentTrends[R]: Anemia Managers - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathy.
Diabetes Week; 11/16/2009; 1185 words; ...BioTrends Research Group, Inc. released three syndicated...study were released and AMAG Pharmaceuticals launched their new IV...ESAs. Familiarity with AMAG's Feraheme, on the...attribute. Keywords: Amgen Inc., Anemia, Aranesp...Metabolism, Nephrology, Pharmaceutical Business, ...

AMAG Pharmaceuticals, Inc. to Participate in the Lazard Capital Markets 6th Annual Healthcare Conference.(Conference news)
Business Wire; 11/12/2009; 521 words; LEXINGTON, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that David Arkowitz, Executive...will be archived on the AMAG Pharmaceuticals, Inc. website until December 2, 2009. About AMAG...

AMAG PHARMACEUTICALS REPORTS MULTIPLE TRANSACTIONS BY 10 PERCENT OWNER ADAGE CAPITAL PARTNERS (Massachusetts)
US Fed News Service, Including US State News; 11/12/2009; 317 words; WASHINGTON, Nov. 12 -- AMAG Pharmaceuticals Inc. (AMAG), Lexington, Mass., has filed a Form 4 with the Securities and Exchange Commission noting the change in the beneficial interest held by 10 percent owner Adage Capital Partners GP LLC...

SSRX, JMBA, ZIOP, GASS, ELRN, ADG Expected To Be Lower After Earnings Releases on Thursday.
M2 Presswire; 11/9/2009; 3195 words; ...quarters Q3 Before GASS StealthGas Inc. 12 quarters Q3 Before ELRN Elron...see if a pattern exists. 3SBio Inc. (NASDAQ: SSRX), a biotechnology...commercialization agreement with AMAG Pharmaceuticals, Inc. for ferumoxytol. The company...